{"id":55777,"date":"2025-07-30T08:45:28","date_gmt":"2025-07-30T08:45:28","guid":{"rendered":"https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/"},"modified":"2025-07-30T08:45:28","modified_gmt":"2025-07-30T08:45:28","slug":"estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/","title":{"rendered":"ESTUDIO EN FASE I\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 %"},"content":{"rendered":"<p>MANUEL COBO DOLS &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; ICON CLINICAL RESEARCH LTD<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MANUEL COBO DOLS &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; ICON CLINICAL RESEARCH LTD<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2683],"tags":[],"class_list":["post-55777","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-22"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ESTUDIO EN FASE I\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 % - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ESTUDIO EN FASE I\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 % - Ibima\" \/>\n<meta property=\"og:description\" content=\"MANUEL COBO DOLS &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; ICON CLINICAL RESEARCH LTD\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:45:28+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"ESTUDIO EN FASE I\\\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 %\",\"datePublished\":\"2025-07-30T08:45:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\\\/\"},\"wordCount\":64,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-22\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\\\/\",\"name\":\"ESTUDIO EN FASE I\\\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 % - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:45:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ESTUDIO EN FASE I\\\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 %\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ESTUDIO EN FASE I\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 % - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/","og_locale":"es_ES","og_type":"article","og_title":"ESTUDIO EN FASE I\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 % - Ibima","og_description":"MANUEL COBO DOLS &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; ICON CLINICAL RESEARCH LTD","og_url":"https:\/\/ibima.eu\/es\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:45:28+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"ESTUDIO EN FASE I\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 %","datePublished":"2025-07-30T08:45:28+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/"},"wordCount":64,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-22"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/","url":"https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/","name":"ESTUDIO EN FASE I\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 % - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:45:28+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-en-fase-i-ii-de-cemiplimab-anticuerpo-anti-pd-1-en-combinacion-con-bnt116-fixvac-de-pulmon-comparado-con-cemiplimab-en-monoterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"ESTUDIO EN FASE I\/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACI\u00d3N CON BNT116 (FIXVAC DE PULM\u00d3N) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA L\u00cdNEA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) AVANZADO CON TUMORES CON EXPRESI\u00d3N DE PD-L1 =50 %"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/55777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=55777"}],"version-history":[{"count":0,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/55777\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=55777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=55777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=55777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}